Valuation: Pluristem Therapeutics Inc.

Market Cap 22.55M 19.71M 18.18M 16.76M 31.59M 2.17B 32.29M 217M 85.49M 1.06B 84.69M 82.83M 3.66B P/E 2024
-1.45x
P/E 2025 -1.39x
Enterprise Value 35.99M 31.45M 29.02M 26.75M 50.42M 3.47B 51.54M 347M 136M 1.7B 135M 132M 5.84B EV / Sales 2024
93.2x
EV / Sales 2025 39.1x
Free-Float
53.43%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 54 29/03/2017
Director of Finance/CFO 42 01/12/2022
Chief Operating Officer - 01/01/2025
Director TitleAgeSince
Director/Board Member 54 01/02/2015
Director/Board Member 56 06/01/2021
Director/Board Member 64 01/06/2021
Change 5-day change 1-year change 3-year change Capi.($)
+11.70%-24.18% - - 20.07M
-1.29%-3.11%-0.35%+2.64% 49.18B
+3.90%-0.39%+386.06%+588.97% 39.58B
-1.70%+4.46%+5.93%+61.54% 34.69B
-2.01%-0.76%+28.41%-8.52% 34.42B
+0.06%+0.34%+2.38%+34.47% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+72.42%+116.45% 15.36B
+1.12%+1.91%+14.54%+15.44% 14.05B
0.00%+1.36%+18.43%-31.23% 13.02B
Average +1.22%+0.03%+65.98%+97.47% 27.07B
Weighted average by Cap. -0.05%-0.18%+79.44%+122.31%

Financials

2024 2025
Net sales 326K 285K 263K 242K 457K 31.39M 467K 3.14M 1.24M 15.38M 1.22M 1.2M 52.93M 1.34M 1.17M 1.08M 993K 1.87M 129M 1.91M 12.88M 5.06M 63.01M 5.02M 4.91M 217M
Net income -20.89M -18.25M -16.84M -15.53M -29.26M -2.01B -29.91M -201M -79.19M -985M -78.44M -76.72M -3.39B -22.58M -19.74M -18.21M -16.79M -31.64M -2.17B -32.34M -218M -85.61M -1.07B -84.81M -82.95M -3.67B
Net Debt -373K -326K -301K -277K -523K -35.92M -534K -3.6M -1.41M -17.59M -1.4M -1.37M -60.56M 13.44M 11.74M 10.84M 9.99M 18.83M 1.29B 19.24M 130M 50.94M 634M 50.46M 49.36M 2.18B
Logo Pluristem Therapeutics Inc.
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
Employees
-